We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Implement Diagnostics System Improves Infectious Disease Testing

By LabMedica International staff writers
Posted on 17 Dec 2019
Print article
Image: Norovirus, which is highly contagious and can survive for days on hard surfaces, infects as many as 700 million people globally every year. PCR.ai is a highly accurate time-saving tool that reduces complexity of qPCR analysis for this and other pathogens (Photo courtesy of Centre for Infection/Public Health England/SP).
Image: Norovirus, which is highly contagious and can survive for days on hard surfaces, infects as many as 700 million people globally every year. PCR.ai is a highly accurate time-saving tool that reduces complexity of qPCR analysis for this and other pathogens (Photo courtesy of Centre for Infection/Public Health England/SP).
A team of scientists recently began using machine-learning tools and assessed them in a prospective clinical trial to determine whether artificial intelligence could perform better than specialists in clinical test interpretation.

The tool automates and standardizes quantitative polymerase chain reaction (PCR) test analysis, enabling real-time monitoring on a test-by-test basis. The company developed the machine-learning system in part to address shortages of trained laboratory staff, as well as to help laboratories improve internal efficiencies, both in terms of time and money saved.

Scientists from Glasgow Royal Infirmary (Glasgow, UK) undertook a prospective clinical study to evaluate the accuracy and impact when automating the manual data-analysis and quality control steps associated with routine clinical pathogen testing using real-time PCR (qPCR). They evaluated the use of the tool when used as a final interpretation and verification step for routine in-house qPCR tests for respiratory pathogens and for norovirus for a total of 22,200 interpretations. The tests were run over the course of a month. The tool is called PCR.ai and is produced by Diagnostics.ai (London, UK).

The team reported that there was 100% concurrence between validated respiratory virus and norovirus detection by their manual routine analysis method and PCR.Ai. Furthermore, there were significant routine savings with PCR.ai of 45 min/respiratory run and 32 min/norovirus run. They concluded that PCR.ai is a highly accurate time-saving tool that reduces complexity of qPCR analysis and hence the need for specialists and hands-on time. It demonstrated capabilities to enable the scientists to get results out more quickly with lower costs and less risk of errors.

Typically, the company works with a lab's existing data, which is fed to the learning machine during a training phase. Any inconsistencies are flagged and dealt with during an interactive phase. Once completed, PCR.ai is handed off to users to run in real-time on a standalone server that is not accessible to the firm. Revenues are derived via a service and support model, influenced by volumes and support needs. The firm's emphasis, however, is on reducing costs within laboratories.

Aron Cohen, BA, CEO of Diagnostics.ai, said, “The model, especially in the UK, tends to be savings driven. I think that's an important approach we have taken, that in addition to improving quality and accuracy, turnaround time, and getting better results faster, reducing costs is a vital piece of that puzzle. Some places have six- or seven-day weeks including night shifts. We need to be able to provide support for that. It's important to have the resources to be able to cope. I think taking in over 20,000 results, and proving we could do it faster, with no errors, and even picking up mistakes made in the manual process are really impressive results for any clinical or AI product.” The study was published in the November, 2019 issue of the Journal of Clinical Virology.

Related Links:
Glasgow Royal Infirmary
Diagnostics.ai

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.